Event-Driven Stocks

BELITE BIO, INC

BLTENasdaq

Healthcare · Pharmaceutical Preparations · E9 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗

Financials

SEC XBRL · annual

No structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
0 acquisitions1 disposalsnet 226 shares · last 1
InsiderDateTypeSharesPrice
Mata Nathan L.Officer — Chief Scientific OfficerMay 7, 2026Sell226$152.45

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.2M9.7-3.4%
Apr 30, 20261.2M11.3+10.6%
Apr 15, 20261.1M7.0+6.7%
Mar 31, 20261.0M6.0+5.5%
Mar 13, 2026990,8335.3+25.1%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Recent SEC filings

All filings ↗
  • 6-KFORM 6-KMay 20, 2026
  • SCHEDULE 13G/AMay 14, 2026
  • 4May 8, 2026
  • 4May 7, 2026
  • 4May 6, 2026
  • 4May 5, 2026
  • 4May 4, 2026
  • 4May 1, 2026
  • 4Apr 30, 2026
  • 4Apr 29, 2026
  • 4Apr 28, 2026
  • 4Apr 27, 2026
  • 4Apr 24, 2026
  • 4Apr 23, 2026
  • 4Apr 23, 2026

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.